189 related articles for article (PubMed ID: 32510625)
1. Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study.
Zhao Y; Wu H; Shi J; Luo Y; Li X; Lan J; Ni W; Lu Y; Chen L; Tan Y; Lai X; Yu J; Huang H
Am J Hematol; 2020 Sep; 95(9):1075-1084. PubMed ID: 32510625
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
Meng G; Wang J; Wang X; Wang Y; Wang Z
Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of anti-human T cell porcine immunoglobulin with recombinant human tumor necrosis factor-α receptor II: IgG Fc in the treatment of 35 cases of grade III/IV acute graft-versus-host disease after allo-HSCT].
Liu DY; Yan S; Ma DD; Zhang C; Fu KB; Liu XM; Liu XH; Wang Y; Li XQ; Zhang JQ; Xiu YY; Peng XJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):743-748. PubMed ID: 33113606
[No Abstract] [Full Text] [Related]
10. Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.
Tan Y; Xiao H; Wu D; Luo Y; Lan J; Liu Q; Yu K; Shi J; He J; Zheng W; Lai X; Zhu Y; Du K; Ye Y; Zhao Y; Zheng G; Hu Y; Han X; Zheng Y; Wei G; Cai Z; Huang H
Oncoimmunology; 2017; 6(3):e1277307. PubMed ID: 28405499
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
13. Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease.
Murray A; Linn SM; Yu B; Novitzky-Basso I; Mattsson J; Kennah M; Elemary M; White J; Lemieux C; Jamani K; Kim DDH
Bone Marrow Transplant; 2024 Jun; 59(6):759-764. PubMed ID: 38402344
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Jagasia M; Perales MA; Schroeder MA; Ali H; Shah NN; Chen YB; Fazal S; Dawkins FW; Arbushites MC; Tian C; Connelly-Smith L; Howell MD; Khoury HJ
Blood; 2020 May; 135(20):1739-1749. PubMed ID: 32160294
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
17. Efficiency and Toxicity of Ruxolitinib as the Salvage Treatment in Steroid-Refractory Acute Graft-Versus-Host Disease after Haplo-Identical Stem Cell Transplantation.
Liu Y; Fan Y; Zhang W; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Transplant Cell Ther; 2021 Apr; 27(4):332.e1-332.e8. PubMed ID: 33836880
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
20. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O; Peczynski C; Boreland W; Lemaitre J; Afanasyeva K; Kornblit B; Jurado M; Martinez C; Natale A; Pérez-Simón JA; Brunello L; Avenoso D; Klein S; Ozkurt ZN; Herrera C; Wichert S; Chiusolo P; Gavriilaki E; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
Front Immunol; 2023; 14():1283034. PubMed ID: 38149251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]